# Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients

> **NCT01803763** · PHASE2,PHASE3 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 30 (actual)

## Conditions studied

- Chronic Urticaria
- Chronic Idiopathic Urticaria
- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** Omalizumab (Xolair)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01803763
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-04-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01803763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01803763, "Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01803763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*